Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report details a middle-aged man with multiple sclerosis who developed difficult-to-evaluate skin reactions after daclizumab treatment, noting only slight improvement with additional therapies.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

This review examines nonmalignant skin toxicities from immunosuppressive and transplant-related medications, emphasizing the need for effective identification and management by care providers; it presents no new research findings.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.